Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PTCers $NXEN expecting CSE listing any day! So many reasons to buy shares. Check out the DD at OwnTheFloat.com.
ARYC’s RECENT Press Releases and important TWEETS:
5-19-18: Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit's new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
https://www.marketwatch.com/story/arrayit-corporation-announces-new-clinical-licensure-from-the-centers-for-medicare-and-medicaid-services-2018-05-09?siteid=bigcharts&dist=bigcharts
5-21-18: Arrayit Corporation Scores 100% on Proficiency Testing Conducted by the College of American Pathologists as clinical team aces CAP PT in highly quantitative measurements of IgE using a blinded study protocol. Congratulations to our amazing clinical team!
http://www.globenewswire.com/news-release/2018/05/16/1507332/0/en/Arrayit-Corporation-Scores-100-on-Proficiency-Testing-Conducted-by-the-College-of-American-Pathologists.html
5-30-18: Sunnyvale, CA , May 30, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has achieved the clinical testing accuracy required for reimbursement under Medicare and Medicaid. Accuracy testing, supervised by the College of American Pathologists (CAP), assesses quantitative measurements of the immunoglobulin E (IgE) regulated analyte in the general immunology proficiency testing program. Arrayit’s testing performance included a score of 100% on the SA-2018 proficiency event and constituted successful cumulative performance required by the Centers for Medicare and Medicaid Services (CMS) over a one-year testing period. CMS regulates approximately 260,000 clinical laboratories through the Clinical Laboratory Improvement Amendments (CLIA) program, and proper certification is required to receive Medicare and Medicaid payments.
https://www.marketwatch.com/story/arrayit-corporation-achieves-testing-accuracy-required-for-medicare-and-medicaid-reimbursement-2018-05-30?siteid=bigcharts&dist=bigcharts
6-18-18: June 18, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives ("sales reps") to sell and distribute the company's allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor's and dentist's offices, health clinics and retail stores into the allergy-testing program.
https://www.marketwatch.com/story/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-distribution-network-2018-06-18?siteid=bigcharts&dist=bigcharts
6-29-18: Arrayit signs capital financing agreement with a top buy-side analyst at a leading corporate intelligence firm headquartered in London UK with offices in New York and providing buy-side intelligence to high net worth retail investors, institutional investors and hedge funds.
https://twitter.com/arrayit/status/1012723616373280768
7-2-18: Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
https://www.marketwatch.com/story/arrayit-corporation-completes-allergy-testing-pilot-program-for-one-of-the-nations-largest-retail-chains-2018-07-02?siteid=bigcharts&dist=bigcharts
7-3-18: Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com
https://twitter.com/arrayit/status/1014187818891935744
7-3-18: Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
https://twitter.com/arrayit/status/1014171600051007488
7-8-18: Arrayit web design team updates investor main page and 33 sub-pages including updated information and links regarding Arrayit technology, auditors, biochemistry 101, celebrity spokesperson, CEO, SEC filings, XBRL filings and many other ARYC investor topics http://arrayit.com/Microarray_Investor/microarray_investor.html …
https://twitter.com/arrayit/status/1016023938470576128
7-16-18: July 16, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company's allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson's Disease (PD).
https://www.marketwatch.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-administration-2018-07-16?siteid=bigcharts&dist=bigcharts
7-25-18: Arrayit senior management completes analyst call with top buy side analyst at the prestigious Alpha Deal Group headquartered in New York NY USA and providing premium independent due diligence for high net-worth retail, instituional and hedge fund customers (link: http://www.alphadealgroup.com) alphadealgroup.com
https://twitter.com/arrayit/status/1022158461302267905
7-30-18: Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of medical clinics nationwide. The network comprises 178 medical clinics in 29 of the 48 contiguous United States including the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions, with single clinics staffing up to 70 physicians. The clinics are using Arrayit allergy testing services to assist physicians in diagnosing and treating allergy and asthma across a wide range of medical specialties and focus areas including anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women’s health.
Arrayit recently established a nationwide sales network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests to medical clinics and retail chains, completed allergy pilot testing with one the nation’s largest chains of retail stores, met with top officials at the United States Food and Drug Administration (FDA) to discuss FDA approval of a major product line, and reported the sale of clinical instrumentation to the FDA. Arrayit microarray tests conveniently use a few drops of patient blood collected on a blood card to assist doctors in identifying and treating food intolerance, allergy and asthma, and pipeline indications for more serious conditions such as ovarian cancer and Parkinson’s Disease. Doctors can use allergy test results as quantitative tools to inform decisions regarding allergy medicines, immunotherapy, food elimination and lifestyle changes.
https://www.marketwatch.com/press-release/arrayit-corporation-signs-allergy-testing-contracts-with-a-nationwide-consortium-of-medical-clinics-2018-07-30?siteid=bigcharts&dist=bigcharts
8-7-18: Arrayit senior management submits $5,000,000 strategic investment proposal to a companion diagnostics and therapeutics leader headquartered in the San Francisco Bay Area USA and commercializing medicines for the massive $45 billion neurodegenerative market
https://twitter.com/arrayit/status/1026860386782339072
8-13-18: August 13, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens. Two thousand retail locations nationwide averaging 3,000 customer visits per store per day would give Arrayit access to 6 million retail customers daily, creating the potential for exponential sales growth. This promotional campaign required rigorous vetting and high-level corporate approval by the retailer, which reports revenues exceeding $50 billion annually.
https://www.marketwatch.com/press-release/arrayit-corporation-receives-approval-for-in-store-promotions-by-a-major-retail-chain-2018-08-13?siteid=bigcharts&dist=bigcharts
8-27-18: August 27, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-partnerships-with-major-allergy-therapeutics-providers-2018-08-27-51843016?siteid=bigcharts&dist=bigcharts
9-10-18: September 10, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit's proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.
https://www.marketwatch.com/press-release/arrayit-corporation-approved-for-direct-medicare-billing-by-the-centers-for-medicare-and-medicaid-services-2018-09-10?siteid=bigcharts&dist=bigcharts
9-24-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports the shipment of clinical instrumentation and quantification software to the United States Food and Drug Administration (FDA). Arrayit uses the same instrumentation and software to test for allergy and food intolerance as well as pipeline indications for ovarian cancer and Parkinson's Disease (PD). Testing is performed in the company's Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the California Department of Public Health (CDPH) and the Center for Medicare and Medicaid Services (CMS).
https://www.marketwatch.com/press-release/arrayit-corporation-ships-clinical-instrumentation-and-software-to-the-united-states-food-and-drug-administration-2018-09-24?siteid=bigcharts&dist=bigcharts
10-8-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen Proficiency Testing (PT) with the College of American Pathologists (CAP). The SC-2017, SA-2018 and SB-2018 triannual CAP Diagnostic Immunology Surveys require highly quantitative measurements of immunoglobulin E (IgE), the antibody molecules measured by the company's finger stick allergy microarray tests. Arrayit's highly accurate PT performance showcases the robustness of the company's proprietary allergy testing platform and reagents, which are increasingly being leveraged by doctors as a tool to diagnose and treat allergy and asthma.
https://www.marketwatch.com/press-release/arrayit-corporation-aces-three-consecutive-rounds-of-proficiency-testing-with-the-college-of-american-pathologists-2018-10-08?siteid=bigcharts&dist=bigcharts
10-22-18: Published: Oct 22, 2018 5:30 a.m. ET
Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, launches a fully automated allergy testing portal for doctors and clinics to streamline and accelerate the allergy testing and treatment process. The Patient Data Solutions (PDS) allergy-testing suite is secure and fully compliant with Health Insurance Portability and Accountability Act (HIPAA) requirements to ensure the privacy of patient health records. The new PDS portal allows doctors to order allergy blood card collection kits, request express mail shipping labels, download allergy test results, and order immunotherapy products from our independent allergy therapeutics partners. The PDS portal, which is free of charge to doctors and clinics, offers continuous, real-time technical assistance to ensure a positive on-line experience.
https://www.marketwatch.com/press-release/arrayit-corporation-launches-patient-data-solutions-allergy-testing-portal-for-doctors-and-clinics-2018-10-22?siteid=bigcharts&dist=bigcharts
10-31-18: Arrayit provides an update to shareholders. We are currently is a quiet period regarding our financials. Our next financial announcement will be the filing of our 10-K and 10-Q forms through 2018. Thanks everyone for your continued support and patience! http://arrayit.com/index.html
https://twitter.com/arrayit/status/1057654833040113665
11-5-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform to a growing number of major market brands. Highly automated Arrayit technology is inherently suited to leveraging multiple brands and their unique venues and relationships to reach a larger number of allergy patients more quickly. Each brand serving major retail chains, large government agencies, medical clinics and doctor offices receive the same high-level testing support and treatment options through the company's Patient Data Solutions (PDS) on-line allergy testing portal and therapeutics affiliates.
Report TOS
Our next pick is NXEM see the link to some good DD .
http://ownthefloat.com/index.php/2018/07/29/ntva-heres-why-i-invested-in-intiva-biopharma/
ALKM), a publicly traded health and wellness technology holding company with a focus on patentable, innovative, and eco-friendly products is pleased to announce that its wholly owned subsidiary, Bell Food and Beverage, Inc. has been awarded a 5-year Production Commitment from Pacific Flavors International Inc., a leading international food supplier and exporter of Oregon Blueberries. We expect this to generate potentially significant revenue for the Company. Today the company has revealed an updated formula improving the shelf life of EVERx. Puration has worked with its co-packer partner, Alkame Holdings, Inc. (USOTC: ALKM) to achieve an enhanced EVERx formulation.
aci ,usmj ,pura, nouv, more to come,Infusing CBD into water is essentially mixing oil and water," said Brian Shibley, CEO of Puration. "The clean, clear look and taste of PURA is a feat in and of itself not achieved by our competitors that hide their water in labels that cover the entire bottle. With exposure to the heat and cold and vibration that comes with shipping and warehousing, we've had some occurrences where our CBD falls out of suspension. We've studied the situation and updated the formula to improve the shelf life of EVERx. At the same time, we've improved the formulation of our flavors to avoid the use of more chemical preservatives. With almost two years of experience under our belt, Puration is substantially ahead of the cannabis beverage market surge."
PTC XALL Due Diligence Report 10/1/18
About Xalles Holdings Inc. (OTC: XALL)
Xalles Holdings Inc. is a holdings company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities to invest and accelerate growth in. Recently, the company has placed emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which will allow for the capture of recurring revenue streams over time. For more information visit: http://xalles.com
Market Cap 444,803 10/1/18
Authorized Shares 500,000,000 9/01/18
Outstanding Shares 83,925,000
Float 57,100,000 8/23/18
https://www.otcmarkets.com/stock/XALL/security
Chart https://www.otcmarkets.com/stock/XALL/overview
The following information can be found at https://www.otcmarkets.com/stock/XALL/news
Xalles and Amazing Living Announce Stock Rewards Program
Press Release | 07/12/2018
WASHINGTON, DC and MARGATE, FL, July 12, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, and its wholly owned subsidiary, Amazing Living Enterprises Inc., a network marketing company focusing on enhancing financial lives through a unique compensation program for affiliates, today jointly announce a significant change to the Amazing Living Affiliate Program with the addition of a Stock Rewards Program.
Starting July 1, 2018, Amazing Living Affiliates will be rewarded through “Amazing Living Dollars” for their activity in the program, purchasing from our eCommerce site, referring others, and loyalty to the company. Once they reach a set threshold of Amazing Living Dollars, they will be issued shares of XALL common stock of equivalent value at the current market price at the time.
“This is a game changer for the eCommerce and Networking industries,” stated Nathan Dickerson, Xalles Holdings Chief Marketing Officer. He continued, “We have an asset in publicly traded stock that has the potential to appreciate, which is the exact opposite of the way most rewards and loyalty programs work. It also creates a new direct incentive for affiliates to work hard to increase the value of their equity in our company.”
The program became effective July 1, 2018 and the company expects to be issuing the first reward shares within a few months, given the fair and reasonable methods that affiliates can use to receive Amazing Living Dollars.
“I am excited to introduce this new program to our affiliates this week as part of the other changes we made to improve the compensation plan for our sales affiliates,” commented Dr. Dennis Grant, President of Amazing Living Enterprises. He added, “we have something unique in the marketplace and we have taken a giant step towards achieving our vision of enhancing financial lives through the distribution of health improvement products.”
Amazing Living brings together a special combination of networking marketing, online commerce and the ability to receive stock in a publicly traded company. Bringing “Wall Street to Main Street” is a noble achievement that is expected to spur new growth in Amazing Living.
Xalles Holdings will continue to strive to offer new marketing and financial solutions and management support to its wholly owned subsidiary companies as part of its business accelerator program.
Xalles Holdings Inc. Announces Management Team Appointments
Press Release | 06/26/2018
WASHINGTON, DC, June 26, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, is announcing recent changes to its management team.
We are pleased to welcome Mr. Paul Erickson as a new member of the board of directors of Xalles Holdings Inc. For over 20 years, Paul has been at the forefront of the Digital Transformation; helping clients to plan for and implement the changes necessary as new disruptive technologies emerge in Banking, Retail, and Technology. He is an innovative and collaborative Executive known for building strong working relationships, mentoring unique talents, and fostering open communications to gain the trust and respect of clients, partners, and key decision-makers. His experience, including most recently as a Partner at IBM Global Business Services, has been on leading cross-functional teams towards the design and execution of transformative programs for internationally-renowned clients including blockchain projects. He has a proven history of overseeing sizeable teams across the complete transformation journey from strategy definition, technology design through to implementation.
Xalles is also announcing the appointment of Mr. Nathan Dickerson to the role of Chief Marketing Officer of Xalles Holdings Inc. Nathan has had a successful career in financial services and in marketing and sales. He worked for a large well-known credit card financial services company both in operations and in human resources. Nathan then worked for a major medical and pharmaceutical distribution company. At their local division, Nathan managed the pharmaceutical division, which included support to acute care hospitals, the U.S Department of Defense as well as other national accounts. Nathan followed his passion into the financial services industry after retiring from the pharmaceutical company. He was recognized as a top producer marketing insurance and financial services products direct to the consumer and did comprehensive financial planning. He is also the author of the book “Live Debt Free”.
“These recent appointments demonstrate our commitment to build a strong, ethical and effective management team and board to help guide Xalles,” said Xalles Holdings CEO, Thomas Nash. He continued, “I am excited to work with the new team members and leverage their experience and skills to achieve our corporate vision and increase shareholder value.”
Xalles Holdings will announce additional management team appointments for key roles in each of its operating subsidiaries in the coming weeks.
Xalles Holdings Inc. Acquires Assets of USA Savings Club
Press Release | 06/20/2018
WASHINGTON, DC. , June 20, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, recently completed an Asset Purchase Agreement for the acquisition of 100% of the assets and intellectual property of www.usasavingsclub.com, a consumer discount shopping club and fundraising service.
Xalles will create a new wholly owned subsidiary to operate an international network of savings clubs based on the USA Savings Club design. The original management team will be part of the new subsidiary and lead the U.S team. Xalles will provide additional resources for domestic growth and international expansion.
USA Savings Club has agreements with thousands of name brand merchants which establishes the base for expansion within the first few regions around the U.S. National brands and local merchants will participate in the program by offering discounts to consumers while supporting local schools and other not-for-profit organizations. Xalles expects to leverage the synergy between this company and the other consumer commerce and payment subsidiaries that are already part of the Xalles family of companies.
“This acquisition gives Xalles the ability to combine strengths of a few of our subsidiaries to offer consumers a way to shop locally at a discount while helping non-profit organizations in their fundraising through a passive and year-round method,” said Xalles CEO, Thomas Nash. He continued, “We believe the combined offering through our existing and new distribution channels will change the way people shop in their local communities.”
Xalles Holdings will continue to search for complementary acquisitions to enhance the consumer’s local shopping and eCommerce experiences.
Xalles Holdings Inc. Preparing Audited Financial Statements for Planned Uplist
Press Release | 05/29/2018
WASHINGTON, DC., May 29, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating Fintech companies, leveraging Blockchain technology for financial reconciliation, and payment auditing solutions, today announces a significant step in its business strategy through creating additional investor opportunities and liquidity.
During the month of June Xalles will be working with its third party PCAOB certified Auditor (Public Company Accounting Oversight Board) to audit the historical financial statements of the companies that Xalles has recently acquired during the past 6 months in addition to the Xalles Holdings financial statements.
The goal of the auditing work that will begin in early June is to enable the company to return to its previous status of fully SEC Reporting. This step will be taken in preparation for the company’s plan to Uplist Xalles to the OTCQB (OTC Markets Quotation Board). The company’s specialized SEC counsel is working with the Xalles management team to prepare the appropriate registration statements and other required documentation. The OTCQB market includes higher standards of transparency and will help Xalles accomplish two of its goals of shareholder liquidity and attraction of new investment capital. The company expects the Uplist process to be completed by August 2018.
The company is also exploring the options for a dual listing on an international exchange once the OTCQB Uplisting process has been completed. This will provide greater global investor access to the company’s securities.
Xalles Holdings will continue to work in parallel to the auditing and Uplisting processes by acquiring new assets and assembling a team of skilled operators.
Xalles Holdings Inc. Reduces Float by More Than 50 Percent
Press Release | 05/22/2018
WASHINGTON, DC, May 22, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, today announces a significant reduction in the number of outstanding and free trading shares of common stock.
Xalles has recently retired 27,000,000 free trading shares, which reduces the free trading float from 53,800,000 shares to 26,800,000 shares, resulting in a 50.19% reduction. This also results in a corresponding reduction in the total number of outstanding common shares from 79,520,000 to 52,520,000.
Information about these reductions on OTC Markets will be reported directly through the transfer agent in the coming days. These recent steps taken are part of Xalles’ promise to increase shareholder value by reducing the number of outstanding shares. This work began last month when Xalles announced on April 25, 2018 that it had reduced the number of outstanding common shares by 180,000,000.
Xalles Holdings will continue to work and build its shareholder value, an effective management team and acquire strategic assets.
Xalles Holdings Announces Transitioning Corporate Structure
Press Release | 05/01/2018
WASHINGTON, DC / ACCESSWIRE / May 1, 2018 / Xalles Holdings Inc. (OTC PINK: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, today announces a status update on its corporate structure transition.
Xalles posted an OTC Markets disclosure on April 6, 2018 indicating that based on the SEC definition of a "shell" that Xalles Holdings had ceased to be a shell based on events in the 4th Quarter of 2017 and the 1st Quarter of 2018. The disclosure links can be found here as reference:
https://www.otcmarkets.com/stock/XALL/disclosure
https://backend.otcmarkets.com/otcapi/company/financial-report/190362/content
As a result of the disclosure statement, OTC Markets removed the "shell" indicator from the company's profile. There is currently an indicator on the OTC Markets site for the XALL profile displaying "Shell Risk". This is an automatic indicator based on the most recent financial statements filed by the company. We expect this indicator to be automatically removed when the company files its Quarterly Financial Statements for 1st Quarter and 2nd Quarter of 2018. Xalles' fiscal year is the same as the calendar year.
Xalles Holdings will be soon announcing new executive team appointments during May as the company continues working to perform against its business plan.
Xalles Holdings Inc. Acquires Co-Owners Rewards Inc.
Press Release | 05/01/2018
Washington D.C., May 01, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, this week executed a Share Purchase Agreement for the acquisition of Co-Owners Rewards Inc., a consumer payment rewards company.
Xalles will leverage this acquisition to expand its reach into the lucrative consumer payments market. Co-Owners Rewards is planning to launch a unique rewards program linked to consumer payment cards and mobile payments. Co-Owners Rewards Inc. is also the sole shareholder of Amazing Living Enterprises Inc., a network and referral marketing firm which currently distributes healthy consumer products, administrates an affiliate management program, and manages a prepaid card program for its members. Amazing Living launched its Amazing Living Mall earlier this year. The “mall” is an e-commerce shopping experience that provides the consumer with access to over 1,200 major retailers and service providers, including Walmart®, BestBuy®, Home Depot®, Expedia®, and many others, but with the added benefit of receiving cash back rebates on each purchase.
“This acquisition gives Xalles two new, foundational building blocks in the consumer e-commerce and payments space,” said Xalles CEO, Thomas Nash. He continued, “We will continue to seek out strategic acquisition targets that will complement these businesses and add value to our company.”
The Co-Owners and Amazing Living acquisition transaction is planned to close on, or before, May 15, 2018. Upon closure, Co-Owners Rewards Inc. and Amazing Living Enterprises Inc. will each become wholly-owned subsidiaries of Xalles Holdings Inc. The share purchase agreement provides the opportunity for current Co-Owners shareholders to become shareholders of Xalles through the recently created Series C Preferred Shares.
Xalles Holdings will provide financial management and information technology support to the two new subsidiaries, to assist in their growth.
Xalles Holdings Inc. Reduces Number of Outstanding Common Shares by More Than 69%
Press Release | 04/25/2018
Washington D.C. , April 25, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, announces the restructuring of its common stock and addition debt reduction it has completed.
Xalles recently took measures to reduce the number of outstanding shares of common stock by more than 69%. This included the cancellation of a block of shares owned by the Xalles CEO, Thomas Nash.
Xalles also recently negotiated the retirement of the convertible notes on its balance sheet. This results in a simpler balance sheet and no remaining notes that can be converted to shares at a discount.
“The recent actions taken to reduce the debt and the number of outstanding shares of XALL common stock demonstrate our management team’s commitment to the company’s 2018 plan and desire to make Xalles more attractive to investors, partners and target acquisition companies,” stated Xalles CEO, Thomas Nash. “I have a long-term vision for this company in the fintech space and I am assembling an executive team that shares my vision.”
Xalles will continue efforts to reduce debt and strengthen its balance sheet while seeking strategic acquisitions.
Xalles Holdings Inc. Acquires Blockchain Development Company, BlockForge Inc.
Press Release | 04/17/2018
Washington D.C., April 17, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, this week executed a Share Purchase Agreement for the acquisition of BlockForge Inc., a blockchain design, development, and implementation firm.
As reported earlier this week, Xalles intends to utilize a blockchain-based platform to overcome client challenges in investment & financing systems (IFS) and financial transaction reconciliation (FTR). The BlockForge acquisition is one step towards successfully implementing these new service offerings, which are a key part of the Xalles business strategy in 2018. Xalles plans to create solutions with the appropriate level of transparency, privacy and operational efficiency, utilizing the company’s core X2X technology.
“The acquisition of BlockForge, Paul Erickson’s management expertise, and the resources he brings to our company will help form the nucleus of our new technology team for focusing on blockchain-based solutions,” said Xalles CEO, Thomas Nash. He continued, “The new team’s first assignment within Xalles will be to help design the new blockchain-based version of the X2X platform, including smart contracts.”
“There is a lot of synergy between BlockForge and Xalles. We both have a vision that will create a new way to support large investment projects, and create operational transparency in process and companies in which investments are deployed,” said BlockForge President, Paul Erickson. “I am excited to see our combined resources create tremendous, innovative solutions in blockchain and other emerging technologies, and to personally be part of the leadership team to realize the joint vision.”
The BlockForge acquisition transaction is planned to close on or before April 30, 2018. Upon closure, BlockForge Inc. will become a wholly-owned subsidiary of Xalles Holdings Inc. The share purchase agreement also provides the opportunity for BlockForge shareholders to become shareholders of Xalles through the recently created Series C Preferred Shares.
Additional updates will follow in the coming weeks as the company continues to execute on its business plan and assembles the corporate components to achieve its goals.
Xalles Holdings Inc. Revamps Business Plan for 2018
Press Release | 04/10/2018
WASHINGTON, DC, April 10, 2018 (GLOBE NEWSWIRE) -- Xalles Holdings Inc. (OTC: XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, recently revised and revamped its business plan to meet the increased demands of the X2X transaction tracking and reconciliation markets.
The core business model for Xalles is setting up “toll gates” for payment transactions to capture revenue from the commerce conducted by government organizations, businesses and consumers. In 2018, the company intends to utilize a blockchain-based platform to meet client challenges in investment & financing systems (IFS) and financial transaction reconciliation (FTR). Open-ledgers and Smart Contracts combined with the intellectual property designed into the company’s X2X system, provide a new, previously inaccessible level of transparency and integrity in these areas.
“Recently, we have seen blockchain take the world by storm,” said CEO Thomas Nash, “Many people have come to realize the technology has tremendous potential, but not as many people have put it to practical use yet. We have an actionable plan to make use of blockchain technology to dramatically improve the transparency, speed, and integrity of the IFS and FTR markets.”
In addition to creating a less error-prone and more trustworthy approach to reconciliation and investment and financing systems, blockchain-based platforms will increase the speed and efficiency of these services. The company will look to a combination of organic development and growth in 2018, plus several strategic acquisitions to enhance the resources and service offerings to consumers, business and government agencies. Xalles’ most recent acquisition was of ArrowVista Corporation, now a wholly owned subsidiary of Xalles, which performs payment audits.
More updates will follow as the company continues to execute on its new business plan and begins putting its blockchain-based platform plan into action through X2X.
Xalles Debt Reduction Announcement
Press Release | 01/17/2018
January 17, 2018
OTC Disclosure & News Service
Washington, DC —
This release includes additional documents. Select the link below to view.
XALL debt reduction release Jan 17 2018.pdf
Financial Reports can be locate at, https://www.otcmarkets.com/stock/XALL/disclosure
Attorney Letter with Respect to Current Information - Attorney Letter regarding 2017 Annual Report
PTCers BIOAQ is running again today don’t miss the opportunity!
We called BIOAQ on Friday it’s up over 100% and climbing on anticipation of good news from court! $$$
PTCers now is a good time to jump into VATE she could be one of the top performers during the rest of 2018. Coffee and Tea are enormous markets and Hemp & CBD versions of both have huge potential!
And too, VATE has recently applied for OTCQB up listing that in its self should make VATE gap up! $$$
WHY I LOVE VATE FOR 2018
There are many reasons why I believe VATE will be one of the top performers during the rest of 2018
Coffee and Tea are enormous markets and Hemp & CBD versions of both have the potential to be blockbuster products
ELEV8 HEMP and ZOE CBD are fantastic brands with well-developed products that possess mainstream potential
VATE has filed its application for QB Uplisting
ELEV8 HEMP COFFEE & TEA ARE BOTH "AMAZON'S CHOICE" AND THE #1 SELLING HEMP COFFEE & TEA IN AMERICA
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140041515
TOP NOTCH BRANDING & MARKETING OF CANNABIS COFFEE
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139537537
ELEV8 HEMP IS BEING SHOWCASED IN NEARLY A DOZEN LUCKY'S MARKET STORES
https://www.instagram.com/p/BeVMpFsjygG/?hl=en&taken-by=elev8hemp
WHY KROGER IS ON THE RADAR
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139546397
THE ZOE CBD OIL PRODUCT LINE IS JUST GETTING STARTED
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140560761
Future products will include Cold Brew Hemp & CBD Coffee in Cans
Future products will also include a full Iineup of Elev8 Full Spectrum Hemp Extract Oil
So VATE is perfectly positioned for Hemp Legalization, as well as Hemp-derived CBD Legalization:
Hemp & CBD Coffee
Hemp & CBD Tea
Cold Brew Hemp & CBD Coffee in Cans
CBD Oil
Everybody has an online presence these days, but they also operate a brick and mortar store where they can showcase their products
The company is self-funding and there is no debt
But most important of all is that...
HEMP WILL BE LEGALIZED IN SEPTEMBER 2018
---
INVESTMENT THESIS FOR VATE
Everybody will be looking to invest in hemp products once hemp is federally legalized in late September
But even before the day it is legalized, as we move through September and draw closer to its legalization, media attention will continue to increase and many new investors will discover that hemp is investable
But similar to MJ stocks (aside from a handful of pharmaceutical plays on the Nasdaq), the only way to gain investment exposure to hemp is on the OTC, due to its federal illegality
There are a huge number of MJ stocks -- over 250 in fact
Yet despite this abundance of MJ stocks, whenever there is a mania, a large majority of these stocks go on tears, and a smaller minority experience epic runups
There are less than a dozen legitimate hemp stocks with products, and on closer examination, only a handful are even worthy of potential investment -- so due to the much smaller sample size, in a Hemp Mania the gains have the potential to be truly astronomical
I looked very closely at all of the hemp stocks last year, and VATE was the best one when taking into account predictive factors that determine the extent of % gains inside of a mania
The masses will pour into VATE the day after hemp is legalized, and for weeks and months afterwards -- I like to get in before the crowd
Check out my track record in the last mania we saw in the MJ sector during 2016
I strongly believe the SUPERMANIA in 2018 will be in Hemp & CBD Beverages and HEMP & CBD COFFEE represents an enormous investment opportunity, particularly because VATE has the #1 selling hemp coffee in America on Amazon (which owns Whole Foods) and is selling out of all inventory regularly at the 12 Lucky's Markets (owned by Kroger) they are showcased in...
As an aside, Hemp and CBD stocks are technically cannabis stocks and therefore considered part of the MJ sector -- so they also participate in any MJ sector manias as well
The same cannot necessarily be said for MJ stocks during a Hemp mania -- we haven't had one yet so we don't know for sure, but it is certainly preferable to own a hemp stock during a hemp mania
Either way, I like the idea of owning a stock that has the potential to participate in both an MJ Mania and a Hemp Mania in 2018
And VATE fits the bill perfectly and is extremely well-positioned to participate in the upcoming 2018 HEMP & CBD BEVERAGE SUPERMANIA, where the biggest % returns in any mania are attained
Sleek
Arrayit Corporation (ARYC) complies with federal rules and regulations governing public companies, including making disclosures with the United States Securities and Exchange Commission (SEC). We will resume quarterly and annual financial filings during the summer of 2018.
http://arrayit.com/Microarray_Investor/ARYC_SEC_Filings/aryc_sec_filings.html
http://arrayit.com/Microarray_Investor/Arrayit_Auditors/arrayit_auditors.html
Arrayit Corporation (ARYC ) is an emerging Biotechnology company in the heart of Silicon Valley. Currently trading at .06/share
https://twitter.com/arrayit
https://www.facebook.com/Arrayit
https://finance.yahoo.com/quote/ARYC?ltr=1
https://www.youtube.com/ ;
Arrayit Corporation News Feed
Arrayit signs $27.1 million term sheet for microarray services with US-based research leader.
http://
arrayit.com/Services/servi
ces.html
…
@Arrayit on Twitter
www.Arrayit.com
A $10,000 investment could easily turn into $200,000. An increase in volume will cause PPS to go vertical. This is your opportunity
Link to their products:
http://www.arrayit.com/Products/products.html
Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD
http://www.
defense.gov
Arrayit schedules business development meeting today with top Vietnamese biotech firm regarding $10MM+ potential microarray growth account.
ARYC quotes $16,000,000 microarray services contract to top US-based research laboratory http://arrayit.com/Services/services.html …
ARYC also owns 40 million shares of AVDX
VATE DD 8/14/18
Business Description
Elev8 Hemp LLC is a newly formed company that plans to bring to market a new premium hemp seed coffee blend. Sipp Industries will be exclusively providing to Elev8 Hemp "proprietary hemp ingredients" for the development of their new hemp coffee brand. Elev8 Hemp Seed Coffee will be the result of the blending of roasted, organic hemp seeds with roasted, organic, Fair-trade Mexican coffee beans that produces a premium, delicious, full-flavored hemp seed coffee that does not leave a bitter aftertaste. Elev8 is also working on Hemp Water products as well as supplements that will focus on the Health and Fitness markets.
http://elev8hemp.com/
Share structure
AS 900 Million 7/20/18
OS 382,885,046
Float 139,187,982 03/31/18
https://www.otcmarkets.com/stock/VATE/security
VATE is a low float MJ company and recently has applied for OTCQB and received approval to sell their products on Amazon Canada. In the past 2 years VATE has traded twice has high as .14.
Elev8 Brands CEO Ryan Medico stated, "Making an international move is a milestone for the Company. Hopefully, this won't be the last. As we lock down the logistics of this move, we plan to expand into other countries as well."
Elev8 Brands, Inc. Application Submitted for Trading on the OTCQB Venture Market https://ih.advfn.com/p.php?pid=nmona&article=78070548
Elev8 Brands, Inc. Acquires L & P Cold Brew, LLC to Enter $71 Billion Market https://ih.advfn.com/p.php?pid=nmona&article=77743478
Three new Elev8 Hemp products enter brick and mortar https://ih.advfn.com/p.php?pid=nmona&article=77226408
Elev8 Brands, Inc.'s Retires Over 200 Million Shares https://ih.advfn.com/p.php?pid=nmona&article=76933438
Elev8 Brands, Inc. Announces Release of New Hemp and CBD Products https://ih.advfn.com/p.php?pid=nmona&article=76676318
List of additional VATE press releases.
https://ih.advfn.com/stock-market/USOTC/elev8-brands-inc-VATE/news
PRMK DD
Previous Owner of PRMK was David Pfister of Integrity Sales & Service, Inc.
Dave Price, went through a divorce back in 2013 and let PRMK delist. Over the past 5 years there has been very few shares traded until just recently 8/3/18. I talked to dave and verified the current share structure is correct with a float of ~35 million shares is accurate.
Dave business model was and is Integrity Sales & Service, Inc. is a commercial market dealer of used trucks and trailer sales, service, and parts from makers like Ford, International, Freightliner, Volvo and others. The Company carries heavy duty inventory including used expedite, box, dump, grain and flatbed trucks, semi tractors, trailers, hot shots, light duty automobiles, and bucket trucks, with a large focus on the agriculture service market in the region. www.99trucks.com
https://www.businesswire.com/news/home/20110419007366/en/ProConcept-Marketing-Completes-Acquisition-Farm-Equipment-Reseller
Previous Owners Letter
https://backend.otcmarkets.com/otcapi/company/financial-report/54424/content
Last listed share structure
https://www.otcmarkets.com/stock/PRMK/security
PRMK applies for reinstatement on 8/2/18
Link to reinstatement
PDF Document
New owner listed
Robert Stevens
38387 Corona Street
Suite 555
Denver, CO 80218
https://www.linkedin.com/in/somersetstevens
ttps://www.somerset.vc
Established in 2005, Somerset Capital is an investment firm based in Denver, Colorado. The firm focuses on making investments in distressed companies, turnaround situations and direct investment in private and pre-public companies.
Owner Robert Stevens
Burntv.com
This Cannabis private company fits nicely. Robert could be using PRMK for this.
https://pitchbook.com/profiles/company/59515-75
Owner Robert Stevens
BKUH Trading at $1.90
iHub https://investorshub.advfn.com/Bakhu-Holdings-Corp-BKUH-15989/
AS 150,000,000
OS 593,037
Float 140,037 as of 1/12/18
10q below
https://ih.advfn.com/p.php?pid=nmona&article=77563485
https://ih.advfn.com/p.php?pid=nmona&article=76248396
https://www.reuters.com/finance/stocks/financial-highlights/BKUH.PK
Edgar Online list of registered documents Showing Roberts Stevens address.
Connected to
SOCIAL LIFE NETWORK, INC.
WDLF Trading at .188
Weedlife.com
https://investorshub.advfn.com/Social-Life-Network-Inc-WDLF-6594/
AS 700,000,000
OS 104,624,609
Float 11,572,117 as of 7/31/18
Owns shares 13,270,000 shares of WLDF
7/10/18 13D
https://www.otcmarkets.com/filing/html?id=12856504&guid=yD9EUFQ6PxPJp3h
Owner Robert Stevens
List of additional Companies Robert Stevens Owns
https://opengovus.com/colorado-business/20141393968#officer
Watching $PRMK for possible MJ company BurnTV merger
INND See Below Why it will run to multiple Dollars Easily!
CEO said they're going for Nasdaq listing to me in an email last night.
The cheapest hearing aid they sell is $499.00. So when they roll out to all Walmart stores, even if they only sell one a week in each store, which doesn't include online sales, they will be bringing in nearly three quarters of a million Dollars, a week! Or that's $38,169,508 per year.
https://www.nohasslehearing.com/
The teeny sound amplifier is $395.00. So if they sell one of those at every Walmart each week that's $581,045 revenue each week or $30,214,340 per year!
https://www.walmart.com/ip/Teeny-Sound-Amplifier-Fits-Either-Ear-Clear-Color-Premium-In-the-Ear-Sound-Amplification/272111527
So, if they only sell only one of the teeny sound amplifier in each Walmart each week (that's the two cheapest models they sell), that will be combined revenues of $68,383,848 per year (for the most basic hearing aid at $499 and the Teeny Sound Amplifier at $395. I'm working on Walmart having 1471 stores in the USA - I'm doing this from memory, so the number of stores might be slightly wrong).
I don't know what their profit margins are but I'd guess they're a very high percentage of the sale price.
The hard work has already been done in product development, tooling up for production, making sure the product works, is easy to use and can be used by the elderly who will also have limited ability to use their hands at their age.
Here's the email the CEO sent to me yesterday which explains the 8K yesterday much better:
I can’t get into the specifics.
Plus I only talk about what has already been disclosed between our filings. I have not talking about anything that has not already been disclosed.
The share increased was solely due to where the stock was at when it was trading around the $.01 to $0.05 range. Just need to increase and have the ability to raise capital or acquisitions of assets or talent.
It was planned out, that we changed our shares to preferred to free up authorized shares to bring in new capital. It was always planned to convert back to common stock once the authorized was approved, which it was approved at the beginning of the week.
InnerScope and the management team is doing everything possible to make a valuable company with great financials and in the coming weeks and months we will be announcing and enacting business plans to make that happen.
So please stay tuned for great news in the coming weeks.
Warm regards,
Matt
Matthew Moore
CEO and Co-Founder
InnerScope Hearing Technologies
Stock Symbol: INND
Corporate Website: www.innd.com
E-Commerce Website: www.NoHassleHearing.com
E-Commerce Website: www.HearingBenefit.com
2151 Professional Drive, 2nd Floor
Roseville, CA., 95661
916-218-4100
Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
$ARYC CLIA clinical team meets with top brass at the United States Food and Drug Administration FDA to discuss FDA approval of a major product line
$ChaChing $ChaChing, i knew this would be a memorable week for ARYC. Grab what you can before it’s too late
Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains
Source: GlobeNewswire Inc.
Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
Arrayit allergy testing is particularly suitable for large retail chains because convenient finger stick sampling allows customers to integrate a physician-ordered allergy test into their real-time shopping experience. The test results, together with patient symptoms and medical history, enable in-store doctors to make personalized medical recommendations about allergy and asthma treatments and medicines, which are also conveniently provided by the retailer. The retail chain, which reports revenues exceeding $50,000,000,000 ($50 billion US dollars) annually, has more than 2,000 locations nationwide.
Arrayit CEO Rene Schena states, “Completing an allergy testing pilot program for a major retailer advances our clinical initiatives. Arrayit personalized allergy testing, in the context of 1,700 sales reps and a large retail chain, would accelerate our mission to provide health and wellness information to millions of American households.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Primary Logo
ARYC Due Diligence link: this is a must read! Check it out!
https://cdn.discordapp.com/attachments/357369664193560596/459932549062590475/Arrayit_Due_Diligence_Report_.pdf
Any new people or folks who haven't seen this yet need to check it out.
Arrayit reports conference call request from a top buy-side analyst at a leading growth markets intelligence firm headquartered in London United Kingdom and providing buy-side business intelligence for retail investors, institutional investors, asset managers and hedge funds.
ARYC huge news out!!!
Sunnyvale, June 18, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network
June 18, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives (“sales reps”) to sell and distribute the company’s allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor’s and dentist’s offices, health clinics and retail stores into the allergy-testing program.
Arrayit allergy tests utilize non-invasive and convenient finger stick sampling and blood card collection, in conjunction with patented and proprietary protein microarray technology, to rapidly and accurately measure immunoglobulin E (IgE) antibodies in the human bloodstream produced by exposure to 120 common food and environmental allergens. Personalized allergy testing assists health care professionals to more easily identify, treat and prevent allergy and asthma by combining molecular testing with a patient’s medical history, symptomology and a physician’s diagnosis. Arrayit allergy tests are manufactured and processed in the company’s Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the State of California and the Centers for Medicare and Medicaid Services (CMS), and benchmarked by the leading laboratory proficiency testing organization, the College of American Pathologists (CAP).
Arrayit CEO Rene Schena states, “We perceive significant synergies between our highly automated allergy testing technology and our newly-contracted network of medical sales professionals working on our behalf to promote allergy testing nationally to patients covered by private and public health insurance. Arrayit finger stick allergy tests are particularly beneficial to pediatric patients, special needs children, seniors, and immunotherapy patients requiring testing at frequent intervals.”
With a little review, it appears that Arrayit is in step 11 in the FDA clearance stage.
https://www.fda.gov/downloads/drugs/resourcesforyou/consumers/ucm284393.pdf
From 1-2-18: Arrayit completes site visit and laboratory tour with a key business-to-business B2B partner and regulatory consultant regarding submission of a proprietary microarray product line to the United States Food and Drug Administration for FDA clearance https://www.fda.gov
From 3-14-18: Arrayit clinical team submits requested standard operating procedures SOPs and other documentation required for submission of a major microarray technology product to the United States Food and Drug Administration FDA for FDA regulatory clearance https://www.fda.gov
From 5-17-18: Arrayit clinical team confirms meeting with the United States Food and Drug Administration FDA to discuss FDA clearance of a major product line. The FDA is headquartered in Silver Spring Maryland USA and improves healthcare by ensuring public safety http://fda.gov
From 5/29/2018 Tweet: Arrayit CLIA clinical team confirms 7/2/2018 meeting with top officials at the United States Food and Drug Administration FDA headquartered in Silver Spring Maryland USA to discuss FDA regulatory clearance of a major microarray technology product line (link: https://www.fda.gov) http://fda.gov
Can you believe Silicon Valley biotech stock ARYC has a market cap under $40m?? Biotech companies have valuations in excess of 50-100 x earnings yet Arrayit is trading at 4x despite having FDA clearance meeting in 3 weeks. RRBB is our auditor and 10k releases could be any day now. I hope you are all seeing how much upside potential this stock has :) Get ready for another huge week, this is just the beginning :)
Replies:
T-23 days for FDA meeting:)
PTCers Congratulations ARYC up 60% today and we are just getting started!
DD on $ARYC:
This microarray company is located in the heart of Silicon Valley, one block from the new Apple headquarters (and another Apple building was just erected on the other side of Arrayit). There is going to be a historical rally at ARYC, it is a Silicon Valley biotech currently trading at under 2 pennies per share and the float is now almost completely locked up.
http://www.arrayit.com/
Facebook page:
Arrayit Corporation
Follow $ARYC on Twitter @Arrayit
http://twitter.com/arrayit
Pinnertest by Arrayit:
Pinnertest utilizes advanced IgG (FC Fragment Specific), Antigen, Antiserum, Control tests to determine an individual’s food sensitivities.
By using this particular kind of test, our lab can thoroughly measure the IgG antibody levels against the proteins of over 200 different foods. This progressive technique works to identify the foods that respond negatively with your system–all with just a few drops of blood dispensed by a basic finger prick.
https://pinnertest.com/frequently-asked-questions/
https://pinnertest.com/order/
https://pinnertest.com/food-sensitivity-test/
https://pinnertest.com/legal-disclaimer/
https://mobile.twitter.com/Pinnertest_USA
Arrayit releases new company newsletter featuring our dynamic business-to-business B2B product Pinnertest which is the market's finest consumer test for dietary wellness and food intolerance based finger stick and advanced microarray testing of 202 foods pinnertest.com
Global DNA Microarray market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including:
Illumnia
Affymetrix
Agilent Technologies
Roche NimbleGen
Arrayit
Applied Microarrays
Biometrix Technology
Savyon Diagnostics
Scienion AG
WaferGen
http://www.kctv5.com/story/35993255/global-dna-microarray-market-top-emerging-factors-to-fuel-the-industry-growth-through-2022
Arrayit to expand our microarray manufacturing capacity by an additional 50% on November 1 2017 for growth accounts arrayit.com/index.html
Arrayit reports $228,000 microarray technology and services lead from top United States Department Agriculture USDA usda.gov
Two contracts signed with major Silicon Valley companies totaling between $48 million and $51 million dollars as posted on their Twitter account @Arrayit
Please begin by following the company on Twitter (@Arrayit $ARYC) for many daily updates. These are free PR's for the company.
Then follow them on Facebook: Arrayit Corporation
If you live in the Bay Area, near Silicon Valley, you can visit the company at:
Arrayit Corporation
927 Thompson Place
Sunnyvale, CA 94085
USA
Phone 408-744-1331
FAX 408-744-1711
Email arrayit@arrayit.com
Web www.arrayit.com
Located in the heart of Silicon Valley near Apple, Yahoo, AMD, Juniper, MBZ, LinkedIn, Facebook and many, many other leaders of the tech industry.
Google their Headquarters:
927 Thompson Place
Sunnyvale, CA 94085
Arrayit updated customer list:
http://www.arrayit.com/Microarray_Investor/Arrayit_Customers/arrayit_customers.html
https://www.nasdaq.com/press-release/arrayit-corporation-announces-new-clinical-licensure-from-the-centers-for-medicare-and-medicaid-20180509-00731
What this means is Arrayit’s blood cards have been given certification by CMS centers for Medicaid and Medicare services and their clinical laboratory amendments program including a license. This all means Arrayit blood cards will be used in any hospital, lab or clinic that partners with Medicaid and Medicare due to the effectiveness, low cost and certification by CMS of the blood cards.
Arrayit blood card Video:
To all who are new to VAPE Marijuana Stock, please review the links provided for this extremely low Market Cap marijuana stock: VAPE (1B OS and 160m Float). Market Cap today is only $4.5 million making it one of the lowest Market Cap Marijuana stocks being traded in the US Market.
Recent 10k and 10q releases by VAPE are highly indicative that VAPE is on track to becoming current within the next few months.
http://quicktake.morningstar.com/stocknet/secdocuments.aspx?symbol=vape
Acquisitions:
As a publicly-traded company (trading under OTCQB: VAPE), Vape Holdings seeks to make corporate acquisitions within our three business verticals.
Vaporizers, Marijuana or cannabis vaporizers, and marketed VAPE brands.
VAPE on Instagram: http://instagram.com/hiveceramics
Twitter: https://twitter.com/hiveceramics
Youtube: https://www.youtube.com/channel/UCFiecGs-LnjolJnCDp9aXKA
Vape Holdings Inc.
Additionally please follow Undervalued_Stocks and Pennytradersclub on Instagram and $VAPE on Twitter
Vaporizers:
Vape Holdings intends to build sales channels within the legal marijuana markets with unique hardware which outperforms the competition. Our products are expected to meet the needs of consumers who use vaporizers for consuming oils, dry herbs, or concentrates.
Building upon a vast base of knowledge, product expertise, and market research — Vape Holdings features a team of domestic engineers in process of creating new devices and intellectual property as future core assets of the company.
With announcements, Vape Holdings is poised to introduce cutting-edge technology specifically for vaporization of cannabis concentrates. Known colloquially as “dabs,” this segment of consumption is wrought with opportunity.
Considered among the first companies to utilize ceramic elements for concentrates, Vape Holdings’ future product line features all-natural, 100% non-porous vaporization elements made for unparalleled taste and purity. The product line will feature a proprietary blend of non-reactive, food grade ceramics providing excellent heat retention, superior corrosion resistance, and unrivaled flavor. Vape Holdings expects to develop a full line of vaporizers which feature this technology, as well as partnerships with other brands who wish to improve the quality and durability of their own product lines.
Future innovations will likely include:
* Vaporizers
* Ceramic elements for OEMs
* Dry herb chambers
* Tooling & OEM / ODM services
Concentrates:
Concentrates refer to the product from extraction of cannabis compounds through the use of a solvent and often sophisticated chemical process. Solvents used in the cannabis extraction process include butane, carbon dioxide, alcohol, or even oxygen.
1) Vape Holdings is currently negotiating with a Colorado state-licensed enterprise to acquire a state-of-the-art cannabis extraction facility, or its production via commercial offtake. As they are available, details will be announced by company press release.
2) Vape Holdings intends to pioneer standards of manufacturing stable, pure, and highly effective concentrates for a variety of purposes within states where marijuana / cannabis are legal.
3) Vape Holdings expects to increase scale after achieving the proposed acquisition of an initial cannabis extraction facility, and replicate this business in other locales or states where cannabis extraction is both legal and commercially viable.
The purpose of extraction is to remove cannabinoids from plant matter in order to create a product with higher purity for personal consumption. By first removing cannabinoids from marijuana plant matter, then removing any potentially harmful solvents utilized in the extraction process — consumers are left with a highly effective and potent product to meet their needs. Cannabis concentrates are used throughout a variety of products, and represent the highest growth vertical within the legal commercial marijuana industry.
Examples of products created from cannabis concentrates, which Vape Holdings intends to produce in licensed facilities or acquire, include:
- “Hash Oil” for vaporization, or simply “oil”
- Edibles such as candies, cookies, sauces, and more
- “Wax,” or solid extracted cannabis compounds
E-cigarettes:
Despite an influx of hundreds of new brands in the e-cigarette business, Vape Holdings is uniquely positioned to succeed within this emerging market on account of its research and team.
Vape Holdings goals for e-cigarettes include:
1) Develop four distinct brands which speak to different, targeted demographics.
2) Partner with existing brands to expand product mix and sales capabilities.
3) Create direct marketing programs for high-margin sales of developed products and brands.
4) Establish wholesale sales channels through in-house B2B sales teams.
5) Align with proven, value-added resellers which already sell into retail chains.
6) Seek “white-label” or co-branding relationships which leverage advertising efforts.
In order to succeed in this fragmented marketplace, especially considering the entry of “big tobacco” and their associated marketing budgets, Vape Holdings has teamed up with two marketing powerhouses in order to improve ROI on marketing investments moving forward.
Media Powers (www.MediaPowers.com) produces quantifiable results, meaning advertising dollars can be tracked to the revenue they generate. When Vape Holdings implements advertising programs, Media Powers is expected to help identify and improve return on investment — ensuring gradual increase in sales and market share for any brands which are developed and introduced.
Vape Holdings’ research indicates that, although a large base of brands exists within the e-cigarette markets — consistent, efficient branding does not. There appear to be only a small handful of efficient brands in this space. With sales figures expected to eclipse $2 billion USD in 2013, the company believes that opportunities abound in this market.
In order to achieve strong brands, Vape Holdings has enlisted the assistance of the award-winning branding experts at HOOK (www.HookUSA.com). A former Ad Age Award Winner for Southeast Agency of the Year — HOOK is expected to help Vape Holdings brands stand out amidst a clutter of competition.
Cannabis Concentrates: State-approved, compliant, licensed facilities in medical marijuana or recreational marijuana-legal states.
E-Cigarettes: Retail stores, existing brands with established sales channels, and proprietary products or technology.
Management:
Benjamin Beaulieu, CEO?Vape Holdings Inc.
https://finance.yahoo.com/news/vape-holdings-releases-earnings-gives-043913158.html
AGOURA HILLS, CA--(Marketwired - Apr 28, 2017) - VAPE Holdings, Inc. ( OTCQB : VAPE ) (the "Company" or "VAPE"), a holding company focused on providing healthy, efficient, and sustainable vaporization products, has filed its quarterly report for the quarter ending June 30, 2016.
"We are getting back on track, we have been making changes and catching up on our filings," stated Benjamin Beaulieu, CEO of VAPE Holdings. "We are comfortable that our financial partners are willing to support us financially as we methodically take steps to catch up on our SEC filings. We know we have to become current on our filings in order to build a sustainable future for VAPE."
"We would like to assure shareholders that business is ongoing and we are working to get the public filings up to date, completing our debt consolidation as well as making key strategic decisions regarding both internal growth and external opportunities in the industry within which we operate," continued Mr. Beaulieu. "In our continuing effort to put things back on the right track, over the past several months we have made strides in resolving several ongoing or potential litigation matters," said Mr. Beaulieu. The Company looks forward to providing more news and disclosure in the coming weeks.
The Company would like to thank the shareholders that participated in the recent survey whereby shareholders could submit questions to management. Management is evaluating the information requests and will communicate any and all information as it becomes available to shareholders and the broader market.
Replies:
Excellent post sir!!
UndervaluedStocks on 5/15/2018 11:38:54 PM
Report TOS
Moderate
“WARNING” Owning shares of ARYC will lead to financial freedom”
VAPE looking really good ran up 27% today very little resistance. Tomorrow should be a repeat
Looks like VAPE is ready to make a run!
New investors in Silicon Valley biotech (trading at .014/share) Arrayit Corporation (ARYC):
@Arrayit on Twitter
Please do your due diligence on this Silicon Valley biotech company and you will see what an extremely undervalued company this is. It is finally getting the attention it deserves
http://www.arrayit.com/
Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
http://stockcharts.com/h-sc/ui?s=Aryc
A list of Arrayit Corporation patents:
https://t.co/EMXlE743rz
Here's a few recent updates from their website. For more links @ Arrayit and $ARYC on Twitter.
Please follow ARYC on Facebook for more updates :)
Arrayit microarray technology platform customers featured widely in Wells Fargo report by top analyst Tim Evans arrayit.com/confidential/l…
Arrayit advances OEM relationship with global medical technology and supply leaders GE Healthcare Chicago IL www3.gehealthcare.com/en
Arrayit featured with market leaders Illumina, Fluidigm and Affymetrix by world business insights leader Owler owler.com
Arrayit reports numerous emails to advance audit completion with top public company accounting firm RRBB Somerset NJ rrbb.com
Arrayit reports $46,000 microarray services sale to a leading proteomics research company located in the central USA
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $190,000 microarray services sale to a top research laboratory located in the Southern United States
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
?@arrayit?
Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India
(link: http://nimhans.ac.in)
nimhans.ac.in
Arrayit reports $35,000 microarray services sale to a leading research laboratory specializing in complex pathways
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $168,000 microarray platform sale to leading medical suppliers Medi Laser located in Lahore Pakistan (link: http://www.medilaser.com.pk) medilaser.com.pk
Arrayit reports $100,000+ microarray services sale to a leading US-based research laboratory (link: http://arrayit.com/Services/services.html) arrayit.com/Services/servi…
Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD
http://www.
defense.gov
Arrayit microarray platform used by customers at University Medicine Bethesda MD to publish cancer research advance
www.twitter.com/arrayit
Arrayit schedules business development meeting today with top Vietnamese biotech firm regarding $10MM+ potential microarray growth account.
Arrayit customers in Toronto Canada use Arrayit microarray technology to publish advance on heart transplantation
http://
journals.plos.org/plosone/articl
e?id=10.1371/journal.pone.0151224
…
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit reports record blood card sales in Q3-16 on microarray immunoassay research apps http://www.arrayit.com/Produc
Arrayit customers in Tel Aviv Israel use Arrayit microarray technology to publish bioprosthetic heart valve advance
http://
onlinelibrary.wiley.com/doi/10.1111/xe
n.12260/full
…
Arrayit quotes $160,000 microarray platform to molecular diagnostic leader Akonni Biosystems http://www.akonni.com
Arrayit reports $18,500 microarray platform sale life sciences leader ChemBio Moscow Russia
?http://www.?
?chembio.ru?
Arrayit reports $34,500 SpotBot 4 Microarray platform sale, leading European Distributor Grupo Taper Sintra Portugal http://www.arrayit.com/Products/Microarrayers/Microarrayer/microarrayer.html …
Arrayit reports microarray sale to testing leader RDL Reference Laboratory Los Angeles CA http://www.rdlinc.com
Arrayit ships $40,000 microarray platform life sciences leader Daemyung Sciences Seoul Korea http://www.dm4you.com
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit customers from Arizona State use Arrayit microarray technology to publish adult stem cell therapy advance
http://www.
sciencedirect.com/science/articl
e/pii/S1873506115000598
…
Can an antibody microarray made with Arrayit technology replace in-situ hybs in HER2 breast cancer diagnostics?...
?http://?
?fb.me/2Xx9b1Oom?
Arrayit reports $30,000 microarray services sale to a top research
Arrayit quotes $179,430 microarrays to biomedical leader Progenie Molecular Valencia España http://www.progenie-molecular.com
Arrayit quotes $51,680 microarrays to top leader De La Salle University Manila Philippines http://www.dlsu.edu.ph
Arrayit quotes $102,240 microarray platform to venture think tank Leading Technology Group http://www.leadingtechnology.co
Arrayit Corporation ?@arrayit
Arrayit completes conference call on huge DNA testing opportunity in massive market in India http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit reports DNA testing inquiry from top agency in India. Market penetration of 0.1% would produce $48M revenues http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit Corporation ?@arrayit
Arrayit quotes $235,000 microarray instruments to top lab University Ottawa Ontario Canada http://www.uottawa.ca
Arrayit reports microarray sale to advanced technology leaders Waki Company Tokyo Japan http://waki-bg.jp
Arrayit reports microarray sale to automated molecular testing leader AutoGenomics Vista CA http://www.autogenomics.com
Arrayit reports microarray sale to life sciences European Biotech Network Dolembreux Belgium http://www.euro-bio-net.com
Arrayit reports microarray sale to top medical researcher at $13.4B endowed MIT Cambridge MA http://web.mit.edu
Arrayit expands marketing on $100K TissueMax™ Automated and Personal Tissue Microarrayers sale
“WARNING” Owning shares of ARYC could lead to financial freedom!
PTCers ARYC & the Iconic lawsuit is dismissed! And Financials are Imminent this going to be a huge week of trading!
PTCers are current picks are ARYC long and we like VAPE for quick in and out, and RCHA in our watch list rumors of a merger
NEW ARYC completes 3-day on-site financial summit in furtherance of audit completion for FY2014-2016 and financial review/audit completion of FY2017 arrayit.com
**BAM** Arrayit advanced microarray technology to be incorporated into a clinical trial by a major pharmaceutical giant in a development that could significantly increase revenues and earnings in 2018 arrayit.com/Products/produ…
$ARYC
Top Stock of 2018!
Happy Holidays!!
1. USDA: Arrayit-USDA food safety test readily detects Listeria monocytogenes implicated in recent food contamination recall freep.com/story/money/bu…
a. Arrayit-USDA miniaturized and multiplexed food safety test can rapidly identify pathogens and increase food safety chicagotribune.com/business/ct-ch…
b. Arrayit-USDA microarray technology food safety test Sensors manuscript published in Google Scholar database mdpi.com/1424-8220/17/9…
c. Arrayit reports $228,000 microarray technology and services lead from top United States Department Agriculture USDA
2. DOD: Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD. http://www.defense.gov
3. Micro array services: Arrayit signs $27.1 million term sheet for microarray services with US-based research leader http://arrayit.com/Services/services.html
a. Arrayit microarray services team completes pilot project for top investigator at the world renowned cancer center Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology MIT in Cambridge Massachusetts USA ki.mit.edu
4. Micro array platforms: Arrayit completes site visit with major European life sciences leader regarding sale of 40 microarray platforms arrayit.com/Products/produ…
a. Arrayit patented and proprietary microarray platform featuring miniaturization, parallelism and automation is well-suited for Global In Vitro Diagnostic Market Boom including in vitro diagnostic IVD tests per top analysts Zacks finance.yahoo.com/news/global-vi…
b. Arrayit microarray technology customers include 8 of the world's top 10 pharmaceutical companies with a combined market cap exceeding $1.4 trillion genengnews.com/the-lists/top-…
c. Arrayit Store sales exceed $55,000,000 all time on 230,706 products and services sold since on-line inception shop.arrayit.com
d. Arrayit proprietary DNA microarray platform well-positioned in the gene expression market which, according to business research leaders MarketsandMarkets™, is expected to reach $5.3 billion by 2020 https://www.marketsandmarkets.com/PressReleases/gene-expression-analysis.asp …
5. Diabetes testing: Arrayit microarray services team accelerates biomarker discovery for growing $32 billion diabetes testing market prweb.com/releases/diabe
6. ARMY: Arrayit reports prostate cancer test sourcing request from United States Army Medical Center Bethesda Maryland usarmy.com
a. Arrayit reports $1,745,000 microarray services inquiry from top government agency United States Army Medical Center
b. Arrayit reports $84,000 microarray platform sale to http://US.Army ;
Medical Research USAMRIID Frederick MD
7. National Institutes of Health: Arrayit submits capabilities statement for major microarray services contract with National Institutes of Health NIH nih.gov
8. Veterinary diagnostics market: Arrayit reports positive steps towards entering the rapidly growing $6.7 billion veterinary diagnostics market with companion animal wellness tests that leverage our patented and proprietary microarray technology petproductnews.com/News/Veterinar
9. B2B partners: Arrayit business-to-business B2B partner Sensovation Radolfzell Germany introduces new SensoSpot® Microarray Analyzers for multiplex-enabled imaging and automated microarray analysis sensovation.com/sensospot
a. Arrayit reports business-to-business B2B expansion opportunity with medical manufacturing leader Anjue Medical China aj-medical.com
b. Arrayit reports successful business expansion conference call with world antibody production leader Abnova Taiwan abnova.com
c. Arrayit reports business expansion opportunity with leading wellness research center headquartered in Cleveland OH arrayit.com/Services/servi…
d. Arrayit business development team reports business-to-business growth opportunity with platform technology leaders Ionica Sciences headquartered at Cornell University in Ithaca New York USA https://www.ionicasci.com
e. Arrayit business development team receives BioPark speed to market and facilities expansion invitation from world healthcare leader GE Healthcare a subsidiary of $151.2 billion General Electric NYSE:GE https://www.gelifesciences.com/country-selection?originalItemPath=%2fFeHH100Y01S0d027000S1vM …
10. FDA: Arrayit reports $155,000 microarray platform RFQ from the United States Food and Drug Administration FDA
11. TELECHEM international is a subsidiary of Arrayit:
https://www.telecheminternational.com/about-us
a. From Dec 22, 2017: Arrayit chemical trading subsidiary TeleChem International Inc reports $8,100 speciality chemical sale to a top industrial supplier headquartered in Arlington Texas https://www.telecheminternational.com
12. Avant Diagnostics, Inc.: ARYC also owns 40 million shares of AVDX. https://www.marketwatch.com/story/avant-diagnostics-newly-appointed-president-ceo-philippe-goix-delivered-an-address-to-shareholders-2017-09-27?siteid=bigcharts&dist=bigcharts
13. ALLERGY TESTING:
a. https://pinnertest.com/
b. http://allergygo.com/
14. New Product: Arrayit's ArrayIt® SuperEpoxy Microarray Substrates provide the highest quality glass microarray printing substrate at an affordable price. All of our substrates are manufactured in state-of-the art class 10 cleanrooms, with 0.1 µm filtered air, and temperature and humidity control. Cleanroom manufacture eliminates contamination of the microarray surface with particulates, proteases, nucleases and other contaminants that impair the quality of microarray experimentation. Compare our SuperEpoxy Substrates to traditional microarray slides and you will see the difference.
15. Other: Arrayit reports positive feedback regarding commercialization opportunity from Columbia Technology Ventures New York techventures.columbia.edu
a. Arrayit reports microarray tech expansion opportunity with largest and strongest eCommerce platform in Japan i-order i-order.asia
b. Arrayit quotes $348,000 annual supply agreement to top wellness testing leader Medica Laboratories Bangkok Thailand http://www.medicalab.co.th
c. Arrayit reports $350,000 microarray services inquiry from leading Veterans Administration Health Care Palo Alto CA
d. Arrayit clinical team completes site visit with clinical experts from a prestigious Northern California hospital and a major governmental approval agency http://arrayit.com/index.html
e. 12-19-17: Arrayit sales and marketing team reports distributorship request from life sciences leaders Elettrofor headquartered in Borsea Italy specializing in research and laboratory instruments and reagents http://www.elettrofor.it/#&panel2-1
f. Arrayit new 12/28/2017 company newsletter features our popular SuperEpoxy 2 Microarray Substrate Slide product line which facilitates a wide spectrum of microarray applications including DNA, protein, antigen, antibody, RPPA and whole cell applications http://arrayit.com/Products/Microarray_Slides/Epoxy_Slides/epoxy_slides.html …
Replies:
And only trading at .009! ARYC is only
Penny Traders Club on 12/30/2017 3:57:01 PM
Report TOS
ARRAYIT mentioned with all the big boys and trading at .0093?
NOVEMBER 23, 2017 BY CRAIG FRANCIS
DNA Microarray Asia-Pacific Market Analysis & Forecast to 2022: Illumnia, Affymetrix, Agilent, Scienion AG, Applied Microarrays, Arrayit, Sengenics
A new research document with title ‘Asia-Pacific DNA Microarray Market by Manufacturers, Regions, Type and Application, Forecast to 2022’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like China, Japan, Korea, Taiwan, Southeast Asia, India, Australia and important players/vendors such as Illumnia, Affymetrix, Agilent, Scienion AG, Applied Microarrays, Arrayit, Sengenics. The report will help user gain market insights, future trends and growth prospects for forecast period of 2017 – 2022
New investors in Silicon Valley biotech (trading just under .01/share) Arrayit Corporation (ARYC):
@Arrayit on Twitter
Please do your due diligence on this Silicon Valley biotech company and you will see what an extremely undervalued company this is. It is finally getting the attention it deserves
http://www.arrayit.com/
Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
http://stockcharts.com/h-sc/ui?s=Aryc
A list of Arrayit Corporation patents:
https://t.co/EMXlE743rz
Here's a few recent updates from their website. For more links @ Arrayit and $ARYC on Twitter.
Please follow ARYC on Facebook for more updates :)
Arrayit microarray technology platform customers featured widely in Wells Fargo report by top analyst Tim Evans arrayit.com/confidential/l…
Arrayit advances OEM relationship with global medical technology and supply leaders GE Healthcare Chicago IL www3.gehealthcare.com/en
Arrayit featured with market leaders Illumina, Fluidigm and Affymetrix by world business insights leader Owler owler.com
Arrayit reports numerous emails to advance audit completion with top public company accounting firm RRBB Somerset NJ rrbb.com
Arrayit reports $46,000 microarray services sale to a leading proteomics research company located in the central USA
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $190,000 microarray services sale to a top research laboratory located in the Southern United States
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
?@arrayit?
Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India
(link: http://nimhans.ac.in)
nimhans.ac.in
Arrayit reports $35,000 microarray services sale to a leading research laboratory specializing in complex pathways
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $168,000 microarray platform sale to leading medical suppliers Medi Laser located in Lahore Pakistan (link: http://www.medilaser.com.pk) medilaser.com.pk
Arrayit reports $100,000+ microarray services sale to a leading US-based research laboratory (link: http://arrayit.com/Services/services.html) arrayit.com/Services/servi…
Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD
http://www.
defense.gov
Arrayit microarray platform used by customers at University Medicine Bethesda MD to publish cancer research advance
www.twitter.com/arrayit
Arrayit schedules business development meeting today with top Vietnamese biotech firm regarding $10MM+ potential microarray growth account.
Arrayit customers in Toronto Canada use Arrayit microarray technology to publish advance on heart transplantation
http://
journals.plos.org/plosone/articl
e?id=10.1371/journal.pone.0151224
…
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit reports record blood card sales in Q3-16 on microarray immunoassay research apps http://www.arrayit.com/Produc
Arrayit customers in Tel Aviv Israel use Arrayit microarray technology to publish bioprosthetic heart valve advance
http://
onlinelibrary.wiley.com/doi/10.1111/xe
n.12260/full
…
Arrayit quotes $160,000 microarray platform to molecular diagnostic leader Akonni Biosystems http://www.akonni.com
Arrayit reports $18,500 microarray platform sale life sciences leader ChemBio Moscow Russia
?http://www.?
?chembio.ru?
Arrayit reports $34,500 SpotBot 4 Microarray platform sale, leading European Distributor Grupo Taper Sintra Portugal http://www.arrayit.com/Products/Microarrayers/Microarrayer/microarrayer.html …
Arrayit reports microarray sale to testing leader RDL Reference Laboratory Los Angeles CA http://www.rdlinc.com
Arrayit ships $40,000 microarray platform life sciences leader Daemyung Sciences Seoul Korea http://www.dm4you.com
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit customers from Arizona State use Arrayit microarray technology to publish adult stem cell therapy advance
http://www.
sciencedirect.com/science/articl
e/pii/S1873506115000598
…
Can an antibody microarray made with Arrayit technology replace in-situ hybs in HER2 breast cancer diagnostics?...
?http://?
?fb.me/2Xx9b1Oom?
Arrayit reports $30,000 microarray services sale to a top research
Arrayit quotes $179,430 microarrays to biomedical leader Progenie Molecular Valencia España http://www.progenie-molecular.com
Arrayit quotes $51,680 microarrays to top leader De La Salle University Manila Philippines http://www.dlsu.edu.ph
Arrayit quotes $102,240 microarray platform to venture think tank Leading Technology Group http://www.leadingtechnology.co
Arrayit Corporation ?@arrayit
Arrayit completes conference call on huge DNA testing opportunity in massive market in India http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit reports DNA testing inquiry from top agency in India. Market penetration of 0.1% would produce $48M revenues http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit Corporation ?@arrayit
Arrayit quotes $235,000 microarray instruments to top lab University Ottawa Ontario Canada http://www.uottawa.ca
Arrayit reports microarray sale to advanced technology leaders Waki Company Tokyo Japan http://waki-bg.jp
Arrayit reports microarray sale to automated molecular testing leader AutoGenomics Vista CA http://www.autogenomics.com
Arrayit reports microarray sale to life sciences European Biotech Network Dolembreux Belgium http://www.euro-bio-net.com
Arrayit reports microarray sale to top medical researcher at $13.4B endowed MIT Cambridge MA http://web.mit.edu
Arrayit expands marketing on $100K TissueMax™ Automated and Personal Tissue Microarrayers sale
Check your g-mail PTC... I sent a pick that could see upwards to a 1,000% w/ the first 400% in one day... management open for conversations... NASDAQ uplist potential...
Thank you PTC! Hope all has been good! $ARYC on high watch!
$ALYE Grossly oversold, book value of est. $2.00, ev/e value (takeover estimate) of $7.35 current pps .3452?!?!?!?!?
http://www.otcmarkets.com/stock/ALYE/filings
A list of ARYC Arrayit Corporation patents:
https://t.co/EMXlE743rz
ARRAYIT mentioned with all the big boys and trading at .0093?
NOVEMBER 23, 2017 BY CRAIG FRANCIS
DNA Microarray Asia-Pacific Market Analysis & Forecast to 2022: Illumnia, Affymetrix, Agilent, Scienion AG, Applied Microarrays, Arrayit, Sengenics
A new research document with title ‘Asia-Pacific DNA Microarray Market by Manufacturers, Regions, Type and Application, Forecast to 2022’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like China, Japan, Korea, Taiwan, Southeast Asia, India, Australia and important players/vendors such as Illumnia, Affymetrix, Agilent, Scienion AG, Applied Microarrays, Arrayit, Sengenics. The report will help user gain market insights, future trends and growth prospects for forecast period of 2017 – 2022
How Many OTC stocks have this much potential?
ARYC Potential revenue streams partial list:
1. USDA: Arrayit-USDA food safety test readily detects Listeria monocytogenes implicated in recent food contamination recall freep.com/story/money/bu…
a. Arrayit-USDA miniaturized and multiplexed food safety test can rapidly identify pathogens and increase food safety chicagotribune.com/business/ct-ch…
b. Arrayit-USDA microarray technology food safety test Sensors manuscript published in Google Scholar database mdpi.com/1424-8220/17/9…
c. Arrayit reports $228,000 microarray technology and services lead from top United States Department Agriculture USDA
2. DOD: Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD. http://www.defense.gov
3. Micro array services: Arrayit signs $27.1 million term sheet for microarray services with US-based research leader http://arrayit.com/Services/services.html
a. Arrayit microarray services team completes pilot project for top investigator at the world renowned cancer center Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology MIT in Cambridge Massachusetts USA ki.mit.edu
4. Micro array platforms: Arrayit completes site visit with major European life sciences leader regarding sale of 40 microarray platforms arrayit.com/Products/produ…
a. Arrayit patented and proprietary microarray platform featuring miniaturization, parallelism and automation is well-suited for Global In Vitro Diagnostic Market Boom including in vitro diagnostic IVD tests per top analysts Zacks finance.yahoo.com/news/global-vi…
b. Arrayit microarray technology customers include 8 of the world's top 10 pharmaceutical companies with a combined market cap exceeding $1.4 trillion genengnews.com/the-lists/top-…
c. Arrayit Store sales exceed $55,000,000 all time on 230,706 products and services sold since on-line inception shop.arrayit.com
5. Diabetes testing: Arrayit microarray services team accelerates biomarker discovery for growing $32 billion diabetes testing market prweb.com/releases/diabe
6. ARMY: Arrayit reports prostate cancer test sourcing request from United States Army Medical Center Bethesda Maryland usarmy.com
a. Arrayit reports $1,745,000 microarray services inquiry from top government agency United States Army Medical Center
b. Arrayit reports $84,000 microarray platform sale to http://US.Army ;
Medical Research USAMRIID Frederick MD
7. National Institutes of Health: Arrayit submits capabilities statement for major microarray services contract with National Institutes of Health NIH nih.gov
8. Veterinary diagnostics market: Arrayit reports positive steps towards entering the rapidly growing $6.7 billion veterinary diagnostics market with companion animal wellness tests that leverage our patented and proprietary microarray technology petproductnews.com/News/Veterinar
9. B2B partners: Arrayit business-to-business B2B partner Sensovation Radolfzell Germany introduces new SensoSpot® Microarray Analyzers for multiplex-enabled imaging and automated microarray analysis sensovation.com/sensospot
a. Arrayit reports business-to-business B2B expansion opportunity with medical manufacturing leader Anjue Medical China aj-medical.com
b. Arrayit reports successful business expansion conference call with world antibody production leader Abnova Taiwan abnova.com
c. Arrayit reports business expansion opportunity with leading wellness research center headquartered in Cleveland OH arrayit.com/Services/servi…
10. FDA: Arrayit reports $155,000 microarray platform RFQ from the United States Food and Drug Administration FDA
11. TELECHEM International is a subsidiary of Arrayit:
https://www.telecheminternational.com/about-us
12. Avant Diagnostics, Inc.: ARYC also owns 40 million shares of AVDX. https://www.marketwatch.com/story/avant-diagnostics-newly-appointed-president-ceo-philippe-goix-delivered-an-address-to-shareholders-2017-09-27?siteid=bigcharts&dist=bigcharts
13. ALLERGY TESTING:
a. https://pinnertest.com/
b. http://allergygo.com/
14. Other: Arrayit reports positive feedback regarding commercialization opportunity from Columbia Technology Ventures New York techventures.columbia.edu
a. Arrayit reports microarray tech expansion opportunity with largest and strongest eCommerce platform in Japan i-order i-order.asia
b. Arrayit quotes $348,000 annual supply agreement to top wellness testing leader Medica Laboratories Bangkok Thailand http://www.medicalab.co.th
c. Arrayit reports $350,000 microarray services inquiry from leading Veterans Administration Health Care Palo Alto CA
Now seriously how many OTC companies have the potential revenue streams like ARYC?
Report TOS
Check out ARYC tweets we see sales like this regularly. IMO, when they get caught up on the financials *BAM* she will bast off heading towards $1or more!
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
414
|
Created
|
07/17/16
|
Type
|
Free
|
Moderator Gold prospector | |||
Assistants PennyStock Alert DDStocks |
No one is responsible for your gains, or losses in the market except YOU. If you follow stocks, strategies discussed on PTC you may LOSE ALL YOUR MONEY. Please weigh the strategies discussed here carefully against what you are willing to risk.
Please do your own due diligence before buying, or selling ANY SECURITY in the open market. There are no guarantees.
PTC nor its club members are NOT Compensated for any current or past mentioned stocks in anyway. Investing in Penny Stocks has a high risk factor and may cause you to lose some or all of your investment.
Never invest in Penny Stocks with money you cannot afford to lose. Please invest wisely after performing your own Due Diligence.
Posts Today
|
0
|
Posts (Total)
|
414
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |